- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04775836
An EHR-based Platform To Facilitate Outcomes and Research Methods in Cerebrovascular Diseases (PLATFORM-CVD)
A Platform for Linking and Assessing To Facilitate Outcomes and Research Methods in CerebroVascular Diseases Using Electronic Health Records (PLATFORM-CVD)
Study Overview
Status
Detailed Description
Adherence to healthcare quality measures is needed to reduce the burden of cerebrovascular disease and improve clinical outcomes. Electronic health records (EHRs) can facilitate the standardization of care provision and the improvement of disease prediction and prevention. Although the EHRs in clinical settings are increasingly prevalent in China, they are rarely used for healthcare research. the investigators aimed to conduct an EHR-based registry study to improve the healthcare and outcomes for cerebrovascular diseases.
Twenty-four hospitals were enrolled in the PLATFORM-CVD Study in January 2018. Data collection began on February 1st, 2019. Historical data from January 2017 are abstracted first and prospective data are continuously reported until May 20th, 2020. Data were abstracted from the medical records, including hospital information system, laboratory information management system, and picture archiving and communication systems by an extract-transform-load tool. The EHR system included diagnostic information for cerebral infarctions (I63), nontraumatic intracerebral hemorrhages (I61), nontraumatic subarachnoid hemorrhages (I60), transient cerebral ischemic attacks and related syndromes (G45), intracranial and intraspinal phlebitis and thrombophlebitis (G08), vascular dementia (F01), and other aneurysms (I72). The quality of stroke care was assessed by 21 evidence-based performance measures. In-hospital outcomes were calculated including mortality, length of stay, and costs.
The PLATFORM-CVD Study leverages EHRs to better understand incident cerebrovascular diseases in China. Data from this cohort will serve as a unique platform for quality assessment and improvement for acute treatment and secondary prevention of cerebrovascular diseases, as well as in-hospital outcome risk predictions and health economic evaluations.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100070
- Recruiting
- Beijing Tiantan Hospital
-
Contact:
- Meng Wang, PhD
- Phone Number: 13261053863
- Email: wangmengpumc@163.com
-
Principal Investigator:
- Zi-Xiao Li, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients were included in the registry if they were hospitalized with a primary diagnose of:
- cerebral infarction (I63)
- nontraumatic intracerebral hemorrhage (I61)
- nontraumatic subarachnoid hemorrhage (I60)
- transient cerebral ischemic attack and related syndromes (G45)
- intracranial and intraspinal phlebitis and thrombophlebitis (G08)
- vascular dementia (F01)
- other aneurysms (I72)
Exclusion Criteria:
- Patients diagnosed with other diseases.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In-hospital mortality
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Patients who died during hospitalization due to cerebrovascular diseases
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Length of stay at hospital
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
The total days for a patients with cerebrovascular diseases at hospitalization
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Costs
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
The total costs for a patients with cerebrovascular diseases at hospitalization
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of antiplatelet medication use
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of antiplatelet therapy during hospitalization
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of dual antiplatelet medication use for non-disabling IS and TIA events
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of aspirin and clopidogrel therapy for ischemic cerebrovascular diseases (IS or TIA) during hospitalization
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of DVT prophylaxis ≤ 48 hours
Time Frame: 48 hours within hospitalization
|
Patients at risk for DVT (non-ambulatory) who received DVT prophylaxis by end of hospital 48 hours, including pneumatic compression, warfarin sodium, and novel oral anticoagulant
|
48 hours within hospitalization
|
Cerebrovascular assessment ≤ seven days
Time Frame: 7 days within hospitalization
|
Cerebrovascular assessment (TCD, IVUS, brain CT or MR scan) within seven days of hospitalization
|
7 days within hospitalization
|
Statin therapy for LDL ≥100 mg/dL during hospitalization
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Lipid lowering agent prescribed during hospitalization if LDL ≥ 100 mg/dL, if patient treated with lipid lowering agent prior to admission, or LDL not documented
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of anticoagulation medication use for atrial fibrillation during hospitalization
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Anticoagulation prescribed during hospitalization in patients with documented atrial fibrillation
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of antithrombotic medication prescribtion at discharge
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Antithrombotic therapy prescribed at discharge, including antiplatelet or anticoagulant therapy
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of antihypertensive medication prescribtion for patients with hypertension at discharge
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Antihypertension medication prescribed at discharge for patients with history of hypertension disease or hypertension disease documented during the hospitalization
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of statin prescribtion for low-density lipoprotein≥100 mg/dL at discharge
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Lipid lowering agent prescribed at discharge if LDL ≥ 100 mg/dL, if patient treated with lipid lowering agent prior to admission, or LDL not documented
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of hypoglycaemia medication prescribtion for diabetes mellitus at discharge
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Hypoglycemic medication prescribed at discharge for patients with history of diabetes mellitus or diabetes mellitus documented during the hospitalization
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of anticoagulation medication prescribtion for atrial fibrillation at discharge
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Anticoagulation prescribed at discharge in patients with documented atrial fibrillation
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of thrombolytic therapy
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Intravenous r-tPA in IS patients
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of thrombectomy therapy
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Thrombectomy therapy for IS patients
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of DVT prophylaxis ≤ 48 hours for ICH
Time Frame: 48 hours within hospitalization
|
Patients with ICH at risk for DVT (non-ambulatory) who received DVT prophylaxis by end of hospital 48 hours, including pneumatic compression.
|
48 hours within hospitalization
|
Rate of antihypertensive medicine use for ICH patients with hypertension at discharge
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Antihypertension medication prescribed at discharge for ICH patients with history of hypertension disease or hypertension disease documented during the hospitalization
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of hypoglycemia medication use for ICH patients with diabetes mellitus at discharge
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Hypoglycemic medication prescribed at discharge for ICH patients with history of diabetes mellitus or diabetes mellitus documented during the hospitalization
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of neurosurgery for ICH patients
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Neurosurgery of ICH include removal of hematoma by craniotomy, aspiration of hematoma by drilling, decompressive craniectomy, ventriculocentesis and drainage, other removal of intracranial hematoma
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of DVT prophylaxis ≤ 48 hours for SAH
Time Frame: 48 hours within hospitalization
|
Patients with SAH at risk for DVT (non-ambulatory) who received DVT prophylaxis by end of hospital 48 hours, including pneumatic compression
|
48 hours within hospitalization
|
Rate of antihypertensive medicine use for SAH patients with hypertension at discharge
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Antihypertension medication prescribed at discharge for SAN patients with history of hypertension disease or hypertension disease documented during the hospitalization
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of hypoglycemia medication use for SAH patients with diabetes mellitus at discharge
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Hypoglycemic medication prescribed at discharge for SAH patients with history of diabetes mellitus or diabetes mellitus documented during the hospitalization
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Rate of neurosurgery for SAH patients
Time Frame: From date of hospitalization until the date of discharge, assessed up to 90 days
|
Neurosurgery of SAH include aneurysm clipping, endovascular embolization of aneurysm, extraventricular shunt
|
From date of hospitalization until the date of discharge, assessed up to 90 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Zi-Xiao Li, PhD, Beijing Tiantan Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Cardiovascular Diseases
- Vascular Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Brain Ischemia
- Stroke
- Brain Infarction
- Intracranial Hemorrhages
- Infarction
- Ischemic Attack, Transient
- Hemorrhage
- Cerebral Infarction
- Subarachnoid Hemorrhage
- Cerebral Hemorrhage
- Cerebrovascular Disorders
Other Study ID Numbers
- 2017YFC1310901
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium